International Multi-Center ADHD Genetics Project

Acquiring DNA Samples
All consent forms stipulate that the samples can only be used by researchers who have been approved by the National Institute of Mental Health (NIMH), National Institutes of Health. All consent forms, except those used at the Zürich site (N=141 subjects), explicitly indicate that the samples may be used by researchers from commercial enterprises seeking to benefit financially from the analysis of the samples. The Zürich consent does not prohibit such use. The Zürich consent form also included an "opt out" that allowed the subjects to indicate that they did not want their samples stored at the NIMH repository or used by researchers external to the project. No subjects enrolled in the project opted out.

Consent groups and participant set

• ADHD (ADHD): 2758 (924 trios)

• Study Weblinks:
  • Upstate Medical University - Medical Genetics Research Center
  • GAIN The Genetic Association Information Network
• Study Design:
  • Family/Twin/Trios
• Study Type:
  • Parent-Offspring Trios
• dbGaP estimated ancestry using GRAF-pop
• Total number of consented subjects: 2758
• Subject Sample Telemetry Report (SSTR)

• BioProject
• PubMed
• BioSample
• MeSH

• Proband diagnosis: combined subtype ADHD
• Children aged 6-17 years (inclusive)
• One or more sibling(s) in the same age range
• Both parents available to provide DNA sample or one parent available plus two or more siblings
• IQ above 70
• Free of single-gene disorders known to be associated with ADHD (e.g. fragile-X, phenylketonuria, hypercalcaemia, thyroid hormone resistance)
• Free of neurological disease and damage (e.g. hemiplegia and other cerebral palsies, epilepsy, hydrocephalus, post- encephalitic syndromes, psychosis, sensorimotor handicaps)
• Living at home with at least one biological parent and one full sibling
• Not meeting criteria for autism or Asperger's syndrome

• Primary Phenotype: Attention Deficit Disorder with Hyperactivity

• Principal Investigator
  • S. Faraone. SUNY Upstate Medical University, Syracuse, NY, USA.
• Site Lead Investigator
  • P. Asherson. Kings College, London, UK.
  • J. Sergeant. Vrije Universiteit, Amsterdam, The Netherlands.
  • R. Ebstein. Hebrew University, Jerusalem, Israel.
  • M. Gill. Trinity Center for Health Sciences, St. James' Hospital, Dublin, Ireland.
  • A. Miranda. University of Valencia, Valencia, Spain.
  • F. Mulas. University of Valencia, Valencia, Spain.
  • R. Oades. University Clinic for Child and Adolescent Psychiatry, Essen, Germany.
  • H. Roeyers. Ghent University, Ghent, Belgium.
  • A. Rothenberger. University of Göttingen, Göttingen, Germany.
  • T. Banaschewski. University of Göttingen, Göttingen, Germany.
  • J. Buitelaar. University Medical Center, Utrecht, The Netherlands.
  • E. Sonuga-Barke. University of Southhampton, Southhampton, UK.
  • B. Franke. University Medical Center, Utrecht, The Netherlands R. Anney, Trinity Center for Health Sciences, St. James' Hospital, Dublin, Ireland.
• Statistical Analysis Team
  • C. Lange. Harvard School of Public Health, Boston, MA, USA.
  • N. Laird. Harvard School of Public Health, Boston, MA, USA.
  • J. Su. SUNY Upstate Medical University, Syracuse, NY, USA.
  • B. Neale. Institute of Psychiatry, London, UK.
  • M. Daly. The Broad Institute of Harvard and MIT, Cambridge Massachusetts, USA.
• Institutions
  • Trinity College, Dublin, Ireland.
  • Ghent University, Ghent, Belgium.
  • Institute of Psychiatry, King's College London, UK.
  • Finanzabteilung Universität, Zürich, Switzerland.
  • Vrije Universiteit, Amsterdam, The Netherlands.
  • University of Göttingen, Germany.
  • Universitätsklinikum Essen, Germany.
  • University of Valencia, Spain.
  • Herzog Hospital, Israel.